Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
2015 ◽
Vol 75
(2)
◽
pp. 332-340
◽
2015 ◽
Vol 75
(2)
◽
pp. 323-331
◽
2018 ◽
Vol 77
(6)
◽
pp. 883-889
◽
2019 ◽